[Effect of novel derivatives of muramyl dipeptide on the immune system]. 1994

O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva

UI MeSH Term Description Entries
D007109 Immunity Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances. Immune Process,Immune Response,Immune Processes,Immune Responses,Process, Immune,Response, Immune
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D000119 Acetylmuramyl-Alanyl-Isoglutamine Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity. Mur-NAc-L-Ala-D-isoGln,Muramyl Dipeptide,Acetylmuramyl Alanyl Isoglutamine,N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide,N-Acetylmuramyl-L-Alanyl-D-Isoglutamine,Alanyl Isoglutamine, Acetylmuramyl,Dipeptide, Muramyl,Isoglutamine, Acetylmuramyl Alanyl,Mur NAc L Ala D isoGln,N Acetyl Muramyl L Alanyl D Glutamic alpha Amide,N Acetylmuramyl L Alanyl D Isoglutamine
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants

Related Publications

O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
January 2001, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
August 1988, Biulleten' eksperimental'noi biologii i meditsiny,
O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
December 1979, Chemical & pharmaceutical bulletin,
O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
November 1989, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
August 1989, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
June 1983, Annals of the New York Academy of Sciences,
O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
August 2014, Bioorganic & medicinal chemistry letters,
O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
January 1999, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
January 1998, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
O V Kaliuzhin, and B B Fuks, and N V Bovin, and A E Zemliakov, and V Ia Chirva
January 1983, Infection and immunity,
Copied contents to your clipboard!